Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03MYO
|
||||
| Former ID |
DIB001166
|
||||
| Drug Name |
MGL-3196
|
||||
| Indication | Hyperlipidaemia [ICD9: 272.0-272.4; ICD10:E78] | Phase 1 | [1] | ||
| Company |
Madrigal pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Target and Pathway | |||||
| Target(s) | Thyroid hormone receptor beta-1 | Target Info | Agonist | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Thyroid hormone signaling pathway | |||||
| Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | ||||
| Reactome | Nuclear Receptor transcription pathway | ||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Hematopoietic Stem Cell Differentiation | |||||
| Nuclear Receptors | |||||
| References | |||||
| REF 1 | Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-beta agonist. Atherosclerosis. 2013 Oct;230(2):373-80. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.